{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-059509","form_type":"8-K","ticker":null,"cik":"0001394319","company_name":"Tracon Pharmaceuticals, Inc.","filed_at":"2024-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.218725+00:00","generated_at":"2026-06-02T00:32:56.230247+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"TRACON reports Q1 net loss $3.2M, cash $8.0M; ENVASARC final data due Q3 2024","bullets":["Net loss for Q1 2024 was $3.2M, down from $8.5M in Q1 2023.","Cash, cash equivalents and restricted cash were $8.0M at March 31, 2024, expected to fund operations late into Q3 2024.","ENVASARC Phase 2 pivotal trial fully enrolled; final response assessment data expected in Q3 2024.","Interim data: ORR 11% by investigator and 5.5% by BICR; median duration of response >6 months.","Nasdaq listing extension granted through June 3, 2024, subject to reverse stock split and S-1 filing (both completed in April 2024)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-059509","json":"https://secwatch.observer/filing/0000950170-24-059509.json","markdown":"https://secwatch.observer/filing/0000950170-24-059509.md","text":"https://secwatch.observer/filing/0000950170-24-059509.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1394319/000095017024059509/0000950170-24-059509-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1394319/000095017024059509/tcon-20240514.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T00:32:56.230247+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8eab2afeac1c631fed702827a3af860f3c7864d9","claim":"Tracon Pharmaceuticals, Inc. reported the first quarter ended March 31, 2024 results: net income Net loss for the first quarter of 2024 was $3.2 million.","evidence_excerpt":"TRACON Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1394319/000095017024059509/0000950170-24-059509-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Net income","value":"Net loss for the first quarter of 2024 was $3.2 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}